Jubilant Life Sciences Limited (JLL) has appointed Gurpartap Singh Sachdeva (Singh) as the Chief Executive Officer (CEO). Singh will have overall responsibility for the operations under Jubilant Pharma and will report to the Jubilant Pharma Board. He will be based in the US.
Prior to Jubilant, Singh had served as President of Sun Pharmaceuticals, US and contributed to the growth of Sun’s US business. He has worked extensively both in India and in the US in various leadership roles pertaining to Strategy, M&A, Commercial and Operations.
The appointment of Singh as the CEO of Jubilant Pharma strengthens the management structure of the company and follows the appointment of Pramod Yadav and Rajesh Srivastava as co-CEOs of the Life Science Ingredients business of JLL.
Shyam S Bhartia, Chairman and Managing Director and Hari S Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences said, “We are pleased to welcome Singh into the Jubilant family to complete our pharma consolidation. Our pharma segment has attained significant scale and the businesses therein have great potential for growth. Singh’s rich experience in pharma industry will help the company to enhance its focus and competitiveness thereby unlocking shareholder value.”
EP News Bureau – Mumbai